Inhibition of Superoxide Generation and Associated Nitrosative Damage Is Involved in Metallothionein Prevention of Diabetic Cardiomyopathy

TABLE 3

Blood pressure and cardiac function in the mice 6 months after STZ treatment

Cardiac function parameters Wild type
MT-TG
Diabetes Control Diabetes Control
Blood pressure
    Systolic pressure (mmHg) 94.9 ± 5.8 95.6 ± 7.0 92.1 ± 2.7 94.8 ± 8.4
    Diastolic pressure (mmHg) 69.7 ± 3.7 76.1 ± 5.5* 68.9 ± 3.3 66.6 ± 8.5
Cardiac function
    Heart rate (bpm) 382.3 ± 12.9 436.5 ± 19.1* 386.2 ± 10.4 399.2 ± 26.7
    LVEDP (mmHg) 8.3 ± 1.8 18.4 ± 4.8* 9.5 ± 2.1 8.4 ± 1.5
    LVMDP (mmHg) −0.9 ± 2.2 12.3 ± 5.5* −1.4 ± 3.6 −4.9 ± 1.8
    LVPSP (mmHg) 98.8 ± 4.0 93.8 ± 5.2 103.2 ± 5.4 108.0 ± 4.9
    Maximum dP/dt (mmHg/s) 8,262.4 ± 524.7 4,183.1 ± 1,287.1* 8,132.0 ± 675.6 9,113.6 ± 692.3
    DCON (ms) 30.1 ± 4.2 29.0 ± 6.3 28.0 ± 2.1 29.6 ± 5.8
    τ (ms) 23.7 ± 2.5 33.1 ± 4.2* 22.0 ± 1.0 24.2 ± 1.1
    Formula R (ms) 45.2 ± 3.6 40.8 ± 3.7 45.7 ± 3.7 47.2 ± 2.2
  • Data are means ± SE (n = 6 or 7). LVPSP, left ventricular peak systolic pressure; DCON, duration of contraction; τ, time constant of relaxation; Formula R, time constant duration of half-relaxation.

  • *

    * P < 0.05 vs. wild-type control.

This Article

  1. Diabetes vol. 54 no. 6 1829-1837